United Therapeutics (UTHR) Reports In-Line Q4 EPS, Beats on Revenues
Tweet
Share
E-mailGet Alerts UTHR Hot Sheet
Price: $540.22 -0.3%
EPS Growth %: +11.9%
Financial Fact:
Basic (in shares): 43.2M
Today's EPS Names:
CRMT, FOMI, FLES, More
EPS Growth %: +11.9%
Financial Fact:
Basic (in shares): 43.2M
Today's EPS Names:
CRMT, FOMI, FLES, More
Join SI Premium – FREE
United Therapeutics (NASDAQ: UTHR) reported Q4 EPS of $3.89, in-line with the analyst estimate of $3.89. Revenue for the quarter came in at $464.7 million versus the consensus estimate of $420.9 million.
For earnings history and earnings-related data on United Therapeutics (UTHR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FactSet (FDS) Tops Q3 EPS by 8c ; Offers Guidance
- Trump discloses over $1.4 billion in crypto income in 2025 filing
- United Therapeutics Corporation Announces FDA Approval of the LungFX™ Device for Centralized Ex Vivo Lung Perfusion
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
